首页> 美国卫生研究院文献>Cancer Medicine >Spatiotemporal heterogeneity of tumor vasculature during tumor growth and antiangiogenic treatment: MRI assessment using permeability and blood volume parameters
【2h】

Spatiotemporal heterogeneity of tumor vasculature during tumor growth and antiangiogenic treatment: MRI assessment using permeability and blood volume parameters

机译:肿瘤生长和抗血管生成治疗期间肿瘤脉管系统的时空异质性:使用通透性和血容量参数进行MRI评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tumor heterogeneity is an important concept when assessing intratumoral variety in vascular phenotypes and responses to antiangiogenic treatment. This study explored spatiotemporal heterogeneity of vascular alterations in C6 glioma mice during tumor growth and antiangiogenic treatment on serial MR examinations (days 0, 4, and 7 from initiation of vehicle or multireceptor tyrosine kinase inhibitor administration). Transvascular permeability (TP) was quantified on dynamic‐contrast‐enhanced MRI (DCE‐MRI) using extravascular extracellular agent (Gd‐DOTA); blood volume (BV) was estimated using intravascular T2 agent (SPION). With regard to region‐dependent variability in vascular phenotypes, the control group demonstrated higher TP in the tumor center than in the periphery, and greater BV in the tumor periphery than in the center. This distribution pattern became more apparent with tumor growth. Antiangiogenic treatment effect was regionally heterogeneous: in the tumor center, treatment significantly suppressed the increase in TP and decrease in BV (ie, typical temporal change in the control group); in the tumor periphery, treatment‐induced vascular alterations were insignificant and BV remained high. On histopathological examination, the control group showed greater CD31, VEGFR2, Ki67, and NG2 expression in the tumor periphery than in the center. After treatment, CD31 and Ki67 expression was significantly suppressed only in the tumor center, whereas VEGFR2 and α‐caspase 3 expression was decreased and style="fixed-case">NG2 expression was increased in the entire tumor. These results demonstrate that style="fixed-case">MRI can reliably depict spatial heterogeneity in tumor vascular phenotypes and antiangiogenic treatment effects. Preserved angiogenic activity (high style="fixed-case">BV on style="fixed-case">MRI and high style="fixed-case">CD31) and proliferation (high Ki67) in the tumor periphery after treatment may provide insights into the mechanism of tumor resistance to antiangiogenic treatment.
机译:当评估血管表型的肿瘤内变异和对抗血管生成治疗的反应时,肿瘤异质性是一个重要的概念。这项研究探讨了C6胶质瘤小鼠在肿瘤生长和抗血管生成治疗过程中的MR血管变化的时空异质性(通过连续MR检查(从开始施用媒介物或多受体酪氨酸激酶抑制剂开始第0、4和7天))。使用血管外细胞外剂(Gd-DOTA)在动态对比增强MRI(DCE-MRI)上量化血管通透性(TP);使用血管内T2药剂(SPION)估计血容量(BV)。关于血管表型的区域依赖性变异性,对照组显示肿瘤中心的TP高于周围,而肿瘤周围的BV高于中心。随着肿瘤的生长,这种分布模式变得更加明显。抗血管生成的治疗效果在区域上是异质的:在肿瘤中心,治疗显着抑制了TP的升高和BV的降低(即对照组中典型的时间变化)。在肿瘤周围,治疗引起的血管改变微不足道,BV仍然很高。在组织病理学检查中,对照组在肿瘤周围的CD31,VEGFR2,Ki67和NG2表达高于中心。治疗后,CD31和Ki67表达仅在肿瘤中心被显着抑制,而整个肿瘤中VEGFR2和α-caspase3表达降低, style =“ fixed-case”> NG 2表达增加。这些结果表明 style =“ fixed-case”> MRI 能够可靠地描述肿瘤血管表型的空间异质性和抗血管生成的治疗作用。保留的血管生成活性(在 style =“ fixed-case”> MRI 上的 style =“ fixed-case”> BV 高和在 style =“ fixed-case”> CD < / span> 31)和治疗后肿瘤周围的增殖(Ki67高)可能为了解肿瘤对抗血管生成治疗的耐药机制提供了见识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号